Mesothelioma Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
9571 Tissue Procurement for Lung Cancer, Esophageal Cancer, Thymoma, and Mesothelioma in Patients Undergoing Surgery or Biopsy
11132A Computerized Analysis of Mesothelioma on Thoracic Computed Tomography Scans
13473A Utilization of Previously Banked Tissue from Patients with Lung Cancer, Mesothelioma, Thymoma/Thymic Carcinoma, and Esophageal Cancer and Correlation with Clinical Data.
10-138-A Dynamic Perfusion Computed Tomography for Malignant Pleural Mesothelioma
Select
10-290-A CALGB 30901: Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients with Malignant Pleural Mesothelioma without Progression after First-Line Chemotherapy
Select
10-652-B Vorinostat and Carboplatin in Patients with Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study
11-0719 AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0980 ADMINISTERED ONCE DAILY IN PATIENTS WITH REFRACTORY SOLID TUMORS OR NON-HODGKIN�S LYMPHOMA
Select
12-0032 Phase II Srudy of Erlotinib for Patients with Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations
12-2200 A Phase IB Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination with Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma
13-0359 A Phase 2b Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.